MedPath

Streptococcus pneumoniae type 4 capsular polysaccharide antigen

Generic Name
Streptococcus pneumoniae type 4 capsular polysaccharide antigen
Brand Names
Pneumovax 23, Prevnar 13, Vaxneuvance
Drug Type
Biotech
Unique Ingredient Identifier
CGS5KI3Q2M
Background

Streptococcus pneumoniae type 4 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 4 of Streptococcus pneumoniae. It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

Associated Conditions
Pneumococcal Infection
Clinical Trials
Related News

Vaxcyte Advances 31-Valent Pneumococcal Vaccine to Final Phase II Stage in Infant Trial

• Vaxcyte has initiated the final stage of Phase II trials for VAX-31, its 31-valent pneumococcal conjugate vaccine, following successful safety review of Stage 1 data in infants. • VAX-31 demonstrates potential to provide approximately 94% coverage against invasive pneumococcal disease and 93% coverage for acute otitis media in U.S. children under five years. • The company expects to report topline data from the primary three-dose immunization series by mid-2026, with booster dose results following approximately nine months later.

FDA Approves Capvaxive, First Adult-Specific 21-Valent Pneumococcal Vaccine

• MSD's Capvaxive, a groundbreaking 21-valent pneumococcal vaccine, receives FDA approval as the first shot specifically designed for adults, covering 84% of invasive pneumococcal disease cases in those over 50. • The vaccine includes eight unique serotypes not found in any other approved pneumococcal vaccine, providing broader protection than Pfizer's Prevnar 20 which covers 52% of cases in adults. • CDC's Advisory Committee on Immunization Practices will meet on June 27th to discuss recommendations for Capvaxive, potentially expanding vaccination guidelines for adults aged 50 and older.

Merck's CAPVAXIVE Receives Positive EU CHMP Opinion for Pneumococcal Vaccine

• The European Medicines Agency's CHMP recommended CAPVAXIVE for active immunization against invasive pneumococcal disease and pneumonia in adults 18 and older. • CAPVAXIVE is designed to protect against Streptococcus pneumoniae serotypes responsible for the majority of invasive pneumococcal disease cases. • The recommendation is supported by Phase 3 STRIDE trial results, evaluating CAPVAXIVE in vaccine-naïve and vaccine-experienced adults. • If approved, this would be the fourth authorization of CAPVAXIVE, having already been approved in the U.S., Canada, and Australia.

Vaxcyte's 31-Strain Pneumococcal Vaccine Shows Superior Immune Response Over Prevnar 20 in Phase 1/2 Trial

Vaxcyte's VAX-31 pneumococcal vaccine demonstrated stronger immune responses against 18 out of 20 serotypes compared to Pfizer's Prevnar 20 in Phase 1/2 trials. The promising results have prompted the company to advance to Phase 3 trials in 2025, potentially challenging Pfizer's dominance in the $10+ billion pneumococcal vaccine market.

Sanofi and SK bioscience's 21-Valent Pneumococcal Vaccine Enters Phase III Trials

• Sanofi and SK bioscience have initiated global Phase III trials for their 21-valent pneumococcal conjugate vaccine candidate, GBP410, targeting individuals aged six weeks to 17 years. • The Phase III program will enroll over 7,700 participants across multiple regions, assessing the vaccine's safety and immunogenicity with varying doses based on age. • This collaboration expands on their existing partnership, with Sanofi paying SK bioscience €50M upfront and potential milestone payments for developing next-generation pneumococcal vaccines. • GBP410 demonstrated comparable immunogenicity and safety to Prevnar 13 in Phase II trials, suggesting its potential to minimize invasive pneumococcal disease in young children.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy